Research Papers:
SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma
Metrics: PDF 1673 views | HTML 2780 views | ?
Abstract
Bin Xu1,*, Min-Hua Ye1,*, Shi-Gang Lv1, Qi-Xue Wang2,3, Miao-Jing Wu1, Bing Xiao1, Chun-Sheng Kang2,3 and Xin-Gen Zhu1
1Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
2Department of Neurosurgery, Tianjin Medical University General Hospital, Heping District, Tianjin, China
3Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Tianjin, China
*These authors have contributed equally to this work
Correspondence to:
Xin-Gen Zhu, email: [email protected]
Chun-sheng Kang, email: [email protected]
Keywords: SNORD47, glioblastoma, cell cycle, proliferation, invasion
Abbreviations: snoRNAs: small nucleolar RNAs; EMT: epithelial-mesenchymal transition; GAS5: growth arrest-specific transcript 5
Received: February 06, 2017 Accepted: March 03, 2017 Published: March 30, 2017
ABSTRACT
SNORD47 is a member of the C/D box small nucleolar RNAs, which have been implicated in cancer development. We intended to investigate the therapeutic potential of SNORD47 in glioma. We found that the expression of SNORD47 was downregulated in glioma tissues samples and inversely associated with advanced tumor stage (WHO grade IV). Kaplan-Meier survival analysis revealed that glioma patients with high SNORD47 expression had longer overall survival than those with low SNORD47 expression. SNORD47 suppressed the proliferation of glioma cells and induced G2 phase arrest. In addition, upregulation of SNORD47 suppressed invasion and epithelial-mesenchymal transition in glioma cells, and combination treatment with lenti-SNORD47 could augment the anti-tumor effect of temozolomide. These results showed that SNORD47 acted as a tumor suppressor in glioma, and provided the potential anti-tumor function in glioma treatment.
![Creative Commons License](/images/80x15.png)
PII: 16693